The Food and Drug Administration (FDA) has granted Orphan Drug Designation to a novel inhaled treatment that could potentially improve lung function in patients with cystic fibrosis (CF).
The treatment, known as SNSP113, is a glycopolymer-based therapy that interacts with structural polymers in protective bacterial biofilms, breaking them apart, and with native glycoproteins in mucus, normalizing mucus viscosity. SNSP113 is intended to improve lung function in CF patients by targeting key drivers of pulmonary decline such as infection, airway congestion and inflammation.
“Because SNSP113 treats the drivers of pulmonary decline rather than the underlying CFTR mutation, it has the potential to treat a broad population of CF patients regardless of genetic mutation,” said Shenda Baker, PhD, CEO of Synspira.
For more information visit Synspira.com.